Vanda Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
Other companies in the scoring industry group for Vanda Pharmaceuticals Inc are displayed. The SDG rating for Vanda Pharmaceuticals Inc represents its transparency towards the UN SDGs. If you work at Vanda Pharmaceuticals Inc and you would like to use your ESG aseessment, please get in touch.
Vanda Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.3; made up of an environmental score of 2.0, social score of 1.6 and governance score of 3.2.
2.3
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1512 | Sol Gel Technologies Ltd | 2.4 | Medium |
1512 | Windtree Therapeutics Inc | 2.4 | Medium |
1529 | Vanda Pharmaceuticals Inc | 2.3 | Medium |
1529 | ANI Pharmaceuticals Inc | 2.3 | Medium |
1529 | Aarti Drugs Ltd | 2.3 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Vanda Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does Vanda Pharmaceuticals Inc disclose current and historical energy intensity?
Does Vanda Pharmaceuticals Inc report the average age of the workforce?
Does Vanda Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does Vanda Pharmaceuticals Inc disclose its ethnicity pay gap?
Does Vanda Pharmaceuticals Inc disclose cybersecurity risks?
Does Vanda Pharmaceuticals Inc offer flexible work?
Does Vanda Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Vanda Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does Vanda Pharmaceuticals Inc conduct supply chain audits?
Does Vanda Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Vanda Pharmaceuticals Inc conduct 360 degree staff reviews?
Does Vanda Pharmaceuticals Inc disclose the individual responsible for D&I?
Does Vanda Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Vanda Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does Vanda Pharmaceuticals Inc disclose water use targets?
Does Vanda Pharmaceuticals Inc have careers partnerships with academic institutions?
Did Vanda Pharmaceuticals Inc have a product recall in the last two years?
Does Vanda Pharmaceuticals Inc disclose incidents of discrimination?
Does Vanda Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has Vanda Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does Vanda Pharmaceuticals Inc disclose parental leave metrics?
Does Vanda Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does Vanda Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Vanda Pharmaceuticals Inc disclose the pay ratio of women to men?
Does Vanda Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does Vanda Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Vanda Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Vanda Pharmaceuticals Inc involved in embryonic stem cell research?
Does Vanda Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does Vanda Pharmaceuticals Inc disclose its waste policy?
Does Vanda Pharmaceuticals Inc report according to TCFD requirements?
Does Vanda Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Vanda Pharmaceuticals Inc disclose energy use targets?
Does Vanda Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Vanda Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Vanda Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.